Absolute Bioavialability of GSK1120212

Summary

A Phase I, single-center, open-label, single-persiod, combined single dose oral and IV microtracer study in subjects with solid tumors.

Timeline

Start

2011-06-20

Primary completion

2011-12-17

Completion

2011-12-17

Publications

• Leonowens C, Pendry C, Bauman J, Young GC, Ho M, Henriquez F, Fang L, Morrison RA, Orford K, Ouellet D. Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours. Br J Clin Pharmacol. 2014 Sep;78(3):524-32. doi: 10.1111/bcp.12373.

Drugs

Indications